AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05230303 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.
Study NCT06259747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acutaping
Description: Application of the kinesio tape on finger and forearm flexor tape after localization of the acupoints of application
Study NCT06259747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxylamine and Pyridoxine
Description: traditional medical treatment for nausea and vomiting during pregnancy
Study NCT06302608 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGGT001
Description: Safety and Effectiveness of subretinal injection of NGGT001 for treating crystalline retinal degeneration
Study NCT05719766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education ,psycological support and social support
Description: we would give targeted-education according to our patients' need(reflected via questionnaire; we would provide psycological and social support to patients based on their need reflected by questionnaire
Study NCT06243328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: negative wound pressure therapy
Description: nonadherent contact layer, such as Xeroform between prepared wound bed and foam then applying a contact dressing with sealling using an adhesive drape. The dressing will be connected to the machine through tubing that was connected to the canister
Study NCT04376424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand Held Ultrasound
Description: Guideline directed medical therapy for heart failure with the addition of hand held ultrasound
Study NCT06699238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise
Description: Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
Study NCT06699238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Standard conventional exercise for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.
Study NCT06699238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise group performed the following training: warm-up for 5 min, walking for 20 min at an intensity that would use 60-70% of the HR reserve, and cool down for 5 min. Additionally, they performed standard conventional exercises at home for 12 weeks, 3 days a week, once a day for 30 min, including cervical, thoracic, and lumbar spine flexibility, shoulder muscles, hip flexors, hamstring and quadriceps muscle stretching, spinal flexor stretching, and extensor strengthening and breathing exercises program was shown by the same physician. Patient compliance with the exercise program was monitored weekly using telemedicine.The aerobic exercise group performed on a treadmill under the supervision of a physician.
Study NCT06699446 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pre rehabilitation
Description: preoperative pre-rehabilitation (respiratory training, exercise therapy). Establish an individualized rehabilitation plan and postoperative communication via telephone or app
Study NCT05156905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab
Description: Cirmtuzumab will be given in combination with docetaxel.
Study NCT04591951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I2-ART
Description: Based on the Parent Empowerment Program model, I2-ART will use methods of adult learning, direct instruction to share knowledge or techniques for practice, modeling, vicarious learning, and practice opportunities (i.e., role rehearsals). The research team will provide the family navigators with 3 months of I2-ART training, including 40 hours of didactic and interactive sessions (10 sessions of 4 hours each). Following training, the family navigators will implement the 3-month I2-ART intervention with the caregivers, including a 2-hour face-to-face meeting, at least three monthly in-person meetings, and intermittent contact between in-person meetings by phone calls, texts or emails, as determined by the family navigator-caregiver dyad.
Study NCT04591951 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Care as usual
Study NCT06389799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: selective fibroblast growth factor receptor (FGFR) inhibitor, oral tablet
Study NCT06389799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: PD-1 inhibitor, Intravenous infusion
Study NCT05744180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Interventional
Description: The FitScore is a machine learning algorithm embedded within the electronic health record that identifies patients most likely to benefit from remote patient monitoring.
Study NCT05918744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Participants will extend their time in bed by one hour for 2 weeks while being monitored.
Study NCT05780658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study NCT05518539 — intervention group
Intervention type: DEVICE
Intervention: The Clareon™ PanOptix™ Trifocal (toric and non-toric models)
Description: Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
Study NCT05731895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 (iclepertin)
Description: BI 425809 (iclepertin)
Study NCT04964531 — intervention group
Intervention type: OTHER
Intervention: speckle tracking echocardiography
Description: before and after closure of the PDA , echocardiographic loops of the apical 4, 3 , and 2 chamber will be acquired then processed by special software for measuring the speckle movements in the longitudinal and short axis views
Study NCT05245318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Clinical care
Description: The standard care treatment comprises 12 face-to-face individual physiotherapy sessions at a ratio of 1 session a week. Every patient in the control group will be treated in a tailored manner according to their results on the baseline measurements. The multimodal treatment program will consist of exercises to increase strength, endurance and coordination of the cervical spine and shoulder stabilising muscles, exercises to increase mobility and improve posture. In case of jaw complaints stretching exercises of the masticatory muscles are added to the program. In addition, manual mobilisations and manual techniques to decrease muscle tension in neck and jaw muscles can be added to the exercise program if necessary. Patients will receive counselling to learn about their neck/jaw complaints but no tinnitus counselling. Patients will be motivated to perform the exercise program at home on a daily basis. Patients will be evaluated weekly.
Study NCT05245318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blended physiotherapy program
Description: The experimental group will receive a blended physiotherapy program consisting of six physiotherapy treatments over a period of 12 weeks, meaning one treatment session every two weeks. In addition, a smartphone application will offer the patients a daily exercise program, based upon the standard physiotherapy treatment, and psychological counselling. Before the start of the program, the exercises will be tailored to the area, type and degree of the patient's dysfunctions. During the six physiotherapy treatment sessions patients will (if needed), receive additional manual mobilisations to increase mobility of the neck and/or temporomandibular joints or manual techniques to decrease muscle tension in neck and jaw muscles. Additional counselling on knowledge about neck and jaw pain and advice about good posture and movement habits will also be provided by the physiotherapist during these six treatment sessions.
Study NCT05599061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Description: Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
Study NCT05599061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FFR>0.80+ OCT with findings indicative of vulnerable plaque
Description: OPTIMAL MEDICAL TREATMENT (OMT)
Study NCT06118606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-manager led multidisciplinary follow-up after intensive care
Description: Early in-hospital follow-up in survivors of intensive care with an increased risk of psychological/physical sequelae. The follow-up is led by a case-manager reassessing the patient after ICU discharge for psychological/physical rehabilitation needs. The CM will discuss patient needs with concerned specialists in a multidisciplinary team, leading to the establishment of a personal rehabilitation plan, communicated to the patient and next-of-kin. The CM will keep track of the patient during hospital stay and ensure primary care rehabilitation (if needed) is established once the patient is discharged from the hospital. The CM will contact the patient weekly to follow up on well-being and primary care activities until 12 weeks after discharge.
Study NCT05710692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 1 mg/kg every 2 weeks
Description: PRX-102 1 mg/kg every 2 weeks
Study NCT06180499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-reg depleted DLI
Description: Treg depleted Donor Lymphocytes Infusion
Study NCT06089733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A ABSK201 and Itraconazole
Description: Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
Study NCT06089733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A ABSK201 and Rifampicin
Description: Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
Study NCT05684692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: A chimeric immunoglobulin G mAb, via intravenous infusion.
Study NCT05684692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe
Description: Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection.
Study NCT05684692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab Matching Placebo
Description: Dextrose 5% in water, via intravenous infusion.
Study NCT05684692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab-Aooe Matching Placebo
Description: 0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection.
Study NCT06698978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simplified protocol (PS)/Conventional protocol (PC)
Description: Complete removable denture according to the simplified protocol (PS) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the conventional protocol (PC) in period 2 (3 months).
Study NCT06698978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional protocol (PC)/Simplified protocol (PS)
Description: Complete removable denture according to the conventional protocol (PC) in period 1 (3 months), 1 month of wash-out then complete removable denture according to the simplified protocol (PS)in period 2 (3 months).
Study NCT06699901 — intervention group
Intervention type: OTHER
Intervention: Massive Transfusion Group
Description: This group includes trauma patients who receive a massive transfusion, defined as the transfusion of at least 3 units of blood. Blood samples are collected at six specific timepoints following the administration of antibiotics to analyze plasma antibiotic concentrations. Existing clinical draws will be used whenever possible to minimize additional venipunctures, with a maximum of two dedicated research-only draws allowed if necessary. Data analysis will assess the impact of large blood transfusions on antibiotic pharmacokinetics over time, adjusting for factors such as kidney function.
Study NCT06699901 — intervention group
Intervention type: OTHER
Intervention: Control Group
Description: This group consists of trauma patients who receive minimal or no blood transfusions (up to 2 units of blood). Blood samples are also collected at six designated timepoints after antibiotic administration to measure plasma antibiotic concentrations. As with the massive transfusion group, clinical draws will be coordinated whenever possible to obtain research samples, with a maximum of two dedicated research-only draws if needed. Data analysis will compare antibiotic concentration trends in this group with those in the massive transfusion group to understand the effects of blood transfusion volume on antibiotic pharmacokinetics.
Study NCT05928845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle thickness measurement
Description: Rectus femoris and sternocleidomastoideus muscle thickness will be measured via ultrasonography in admission and on 7th day of admission
Study NCT04566250 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Opioid Prescription and Infographic
Description: The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.
Study NCT04566250 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Non-Opioid Prescription and Infographic
Description: The study intervention will involve 3 components:~1. A standardized non-opioid prescription: A prescription for Naproxen 500mg PO BID PRN x 60 tabs, Acetaminophen 1000mg PO Q6H PRN x 100 500mg tabs and Pantoprazole 40mg PO daily x 30 tabs (to be taken only while utilizing Naproxen).~2. A limited opioid rescue prescription: A prescription of Hydromorphone 1mg PO Q4H PRN x 10 tabs will be included on a separate prescription.~3. Patient education infographic: The infographic will contain information on how to take the prescribed medications, along with instructions that the morphine rescue prescription should only be used in cases where the non-opioid pain medications are not providing satisfactory pain control.
Study NCT05220501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Micro-US Targeted Biopsy
Description: All subjects will be biopsied no matter their arm randomization. In this group, MicroUS targets will be identified and sampled.
Study NCT04838639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NO-13065
Description: Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.~Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.
Study NCT04838639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects per cohort will take a matched placebo.
Study NCT05620485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted CDC excision and hepaticojejunostomy
Description: After birth, the liver and gallbladder ultrasound were regularly rechecked. If the maximum diameter of the cyst was greater than 5 cm, surgery was performed.
Study NCT05710692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 2 mg/kg every 4 weeks
Description: PRX-102 2 mg/kg every 4 weeks
Study NCT05482594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: During routine blood sampling, serum after centrifugation will be stored and frozen at -80°C in the immunology laboratory in order to carry out analyzes by the ELISA method to measure the levels of SCF.
Study NCT05482594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videocapillaroscopy
Description: Videocapillaroscopy is a non-invasive and safe method for the morphological examination and the analysis of abnormalities of the microcirculation linked in particular to systemic scleroderma. Here it is a digital capillaroscopy used routinely at the CHU Brugmann, in the follow-up of patients and whose results will be collected in this study.
Study NCT05053074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow (NHF)
Description: Patients with chronic respiratory failure are treated for 1 h with NHF therapy and with individual O2 supplementation during wakefulness.
Study NCT05746689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
Study NCT05432895 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic splint
Description: Device treats plantar fasciitis and replacing boot immobilization which is quite benign
Study NCT06005532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab injection 40 mg / 0.8 ml
Study NCT06005532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Adalimumab injection 40 mg / 0.4 ml
Study NCT05561283 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Self-questionnaires
Description: Self-questionnaires on satisfaction, burn-out, depression, anxiety, relational skills and sleep quality
Study NCT05220501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI Targeted Biopsy
Description: All subjects will be biopsied no matter their arm randomization. In this group, MRI targets will be identified and sampled.
Study NCT04971122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Trendeleburg -5 degree,-10 degree,-15 degree
Description: Use a -5 or -10 or -15 degree trendelenburg position
Study NCT06454682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJK002 Intrathecal injection
Description: Eligible subjects will receive a single intrathecal administration of investigational product with dose 6E13 vg/person, 1.2E14 vg/person, and 2.4E14 vg/person sequentially.
Study NCT06450301 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial biopsies are commonly done to check for the window of implantation, to determine ovulation or for enhancing implantation (procedure called endometrial scratching). For this purpose, we will use a Pipelle catheter. This procedure is very common in gynecologic practice and~generally considered safe. In most of the cases this procedure is indicated for evaluation of irregular vaginal bleeding, vaginal bleeding in post-menopausal women and for infertility related problems (recurrent implantation failures for example).
Study NCT05432895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic splint
Description: Device treats plantar fasciitis and replacing boot immobilization which is quite benign
Study NCT06407336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Description: Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
Study NCT06407336 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Refraction
Description: Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.
Study NCT06172322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ1062 with Fulvestrant
Description: Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment).~Drug: Fulvestrant Injection 500mg in a 28-day cycle.